Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 150

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 150
---
 healthy adults. Both formulations of SPN-443 showed adequate bioavailability and were well tolerated. The Company expects to disclose a lead indication for the product candidate by the end of 2025.

Critical Accounting Policies and the Use of Estimates

A summary of our significant accounting policies is included in Note 2, Summary of Significant Accounting Policies of our audited consolidated financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2024. There were no significant changes to the disclosures with respect to our critical accounting policies in our Annual Report on Form 10-K for the year ended December 31, 2024.

29

Results of Operations

Comparison of the Three and Six Months ended Months Ended June 30, 2025 and 2024 

Revenues

Revenues consist primarily of net product sales of our commercial products in the U.S., supplemented by royalty and licensing revenues from our collaborative licensing arrangements. The following table provides information regarding our revenues during the three and six months ended months ended June 30, 2025 (dollars in thousands):Three Months Ended June 30,ChangeSix Months EndedJune 30,Change20252024AmountPercent20252024AmountPercentNet product salesQelbree$77,547 $59,395 $18,152 31%$142,292 $104,499 $37,793 36%GOCOVRI36,660 31,703 4,957 16%67,349 58,265 9,084 16%APOKYN12,820 17,295 (4,475)(26)%27,796 33,944 (6,148)(18)%Trokendi XR11,193 17,086 (5,893)(34)%23,994 33,075 (9,081)(27)%Oxtellar XR11,637 29,516 (17,879)(61)%21,835 56,459 (34,624)(61)%ONAPGO1,604 — 1,604 100 %1,604 — 1,604 100 %Other(1)6,534 7,543 (1,009)(13)%15,113 14,757 356 2%Total net product sales157,995 162,538 (4,543)(3)%299,983 300,999 (1,